MYNEO THERAPEUTICS
Innovating immunotherapies, transforming tomorrow
myNEO Therapeutics is a distinguished biopharmaceutical powerhouse, dedicated to pioneer breakthrough immunotherapies to fight cancer. We are leveraging our neoantigen discovery ImmunoEngine platform to tap into novel promising tumor targets found in the dark genome – named camyotopes™ – which have the potential to unlock immunotherapy for large patient populations who do currently not respond.
Tapping into the dark genome
We unravel the untranslated dark language of the tumor genome.
Leveraging best-in-class IO targets
We discover more and better targets with our proprietary myNEO™ technology.
Crafting a new future for cancer therapy
We pioneer breakthrough immunotherapies with data-driven precision.
CAMYOTOPES
A novel dark antigen class
We believe camyotopes are a game changing set of tumor targets with unparalleled potential for therapeutic cancer vaccine development.
Specific translation in cancer
Very high abundance within patients
Exceptional immunogenicity
Unlocking first-in-class targets from the under-exploited dark genome.
More than 95% target population coverage
Innovating immunotherapies,
transforming tomorrow
Subscribe to our newsletter
Get the latest news & updates about myNEO Therapeutics
Home
About us
Products
Technology
Partners
Services
Contact
Quick links
Publications
Latest news
Privacy statement
Terms of use
Careers
Cookie statement
We use cookies to enhance your browsing experience and provide analytics. By continuing to use this website, you agree to our use of cookies. For more information, please read our privacy statement.
myNEO BV
Ottergemsesteenweg-Zuid 808 B511, 9000 Ghent, East-Flanders
Belgium (BE0715710837)
Design by
